Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Eyestem completes first round of patient injections for its dry AMD treatment

Eyestem completes first round of patient injections for its dry AMD treatment

David Hutton
September 9th 2024
Article
Diagnos Inc. meets compliance requirements for ISO 13485 standard

Diagnos Inc. meets compliance requirements for ISO 13485 standard

Sydney M Crago
September 2nd 2024
Article
Clearside Biomedical complete final participant visit in ODYSSEY phase 2b trial

Clearside Biomedical complete final participant visit in ODYSSEY phase 2b trial

Sydney M Crago
September 1st 2024
Article
Formulation and use patent issued to InMed for ocular delivery candidate

Formulation and use patent issued to InMed for ocular delivery candidate

Sydney M Crago
August 30th 2024
Article
University of Minnesota researchers uncover possible pathway to prevent AMD

University of Minnesota researchers uncover possible pathway to prevent AMD

David Hutton
August 23rd 2024
Article
Sandoz receives FDA approval for aflibercept-abzv for the treatment of nAMD

Sandoz receives FDA approval for aflibercept-abzv for the treatment of nAMD

David Hutton
August 12th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.